Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Investing Activities: 2012-2025

Historic Cash from Investing Activities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $2.3 million.

  • Enanta Pharmaceuticals' Cash from Investing Activities fell 87.96% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.3 million, marking a year-over-year decrease of 30.72%. This contributed to the annual value of $40.3 million for FY2025, which is 30.72% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Cash from Investing Activities stood at $2.3 million for Q3 2025, which was up 108.67% from -$26.5 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Cash from Investing Activities ranged from a high of $72.7 million in Q3 2021 and a low of -$145.7 million during Q2 2023.
  • Its 3-year average for Cash from Investing Activities is $1.0 million, with a median of $2.3 million in 2025.
  • In the last 5 years, Enanta Pharmaceuticals' Cash from Investing Activities surged by 2,802.68% in 2021 and then slumped by 998.57% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at $45.5 million in 2021, then declined by 26.22% to $33.6 million in 2022, then slumped by 139.07% to -$13.1 million in 2023, then spiked by 625.30% to $68.9 million in 2024, then crashed by 87.96% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, -$26.5 million for Q2 2025, and -$4.4 million during Q1 2025.